Open Nav

CFIUS and You: Understanding the Newly Expanded Regulatory Reviews of Cross-Border Investments

  • Lisa Schaefer, BIO,
  • Thilo Hanemann , Rhodium Group,
  • Louis Lehot, DLA Piper,
  • Mark E. Plotkin, Covington & Burling LLP

In August 2018, President Trump signed into law new rules regarding foreign direct investment in U.S. companies that any cross-border equity investor, dealmaker, or CEO seeking funding should incorporate into their planning. The Committee on Foreign Investment in the United States (CFIUS), which has mostly focused on national security reviews of acquisitions in military technology industries, now will devote additional resources to scrutinize venture capital and minority-investment deals where companies possess sensitive, personal data of U.S. citizens. Some previously voluntary deal notification filings will become mandatory, with penalties for noncompliance. This panel will examine the impact that these new investment rules will have on the biotechnology sector. Expert speakers will describe the government review process and provide guidance on when incorporating a potential CFIUS review into deal negotiations makes sense.

Moderator: Lisa Schaefer, Director, Tax & Financial Services Policy, Biotechnology Innovation Organization

  • Date:Wednesday, October 17
  • Time:3:15 PM - 4:10 PM
  • Session Type:Educational Session
Lisa Schaefer
Thilo Hanemann
Rhodium Group
Louis Lehot
DLA Piper
Mark E. Plotkin
Covington & Burling LLP